Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Vaxcyte, Inc. Director's Dealing 2021

Dec 20, 2021

31100_dirs_2021-12-20_afe77bce-4907-48e1-a827-03d61b0efa6d.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Vaxcyte, Inc. (PCVX)
CIK: 0001649094
Period of Report: 2021-12-16

Reporting Person: Fairman Jeff (VP, Research)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2021-12-16 Common Stock M 4619 $1.79 Acquired 10779 Direct
2021-12-16 Common Stock S 4619 $22.50 Disposed 6160 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2021-12-16 Stock Option (right to buy) $1.79 M 4619 Disposed 2027-05-17 Common Stock (4619) Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 341227 Indirect
Common Stock 50000 Indirect

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.

F2: The shares subject to the option are fully vested and exercisable.